HNSBF News and Press, Hansa Biopharma AB

2026-02-11 14:54:23 ET Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call February 11, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Hansa Biopharma AB (publ) (HNSBF) Q4 2025 Earnings Call Transcript

2026-02-11 05:05:23 ET More on Hansa Biopharma Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Seeking Alpha’s Quant Rating on Hansa Biopharma Historical earnings data for Hansa Biopharma Financial...

2026-01-14 16:16:03 ET Hansa Biopharma AB (publ) (HNSBF) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Hansa Biopharma AB (publ) (HNSBF) Presents at 44th Annual J.P. Morgan Health...

2025-11-12 13:11:31 ET Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases November 12, 2025 9:00 AM EST... Read the full article on Seeking Alpha For further details see: ...

2025-10-30 19:46:28 ET Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Hansa Biopharma AB (publ) (HNSBF) Q3 2025 Earnings Call Transcript

2025-10-30 08:45:01 ET More on Hansa Biopharma Hansa Biopharma AB (publ) Discusses on ConfIdeS US Phase 3 Pivotal Trial Topline Results Presentation Hansa Biopharma AB (Publ) Discusses On ConfIdeS US Phase 3 Pivotal Trial Topline Results Call (Transcript) Seeking Alp...

2025-10-29 06:15:08 ET Jefferies analyst issues BUY recommendation for HNSBF on October 29, 2025 08:44AM ET. HNSBF was trading at $4.58 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...

2025-09-25 11:07:48 ET Hansa Biopharma AB (publ) - Special Call Company Participants Renee Aguiar-Lucander - Chief Executive Officer Richard Philipson - Chief Medical Officer Monika Tornsen - COO & President of U.S. Angela Maldonado ... Read the...

Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation PR Newswire At 12 months, mean eGFR was 51.5 mL/min/ 1.73m 2 in the imlifidase arm versus 19.3 mL/min/ 1.73m 2 in the control arm with a statisticall...

2025-07-17 10:46:16 ET Hansa Biopharma AB (publ) (HNSBF) Q2 2025 Earnings Conference Call July 17, 2025, 8:00 AM ET Company Participants C. Evan Ballantyne - CFO & Senior VP Hitto Kaufmann - Senior VP, Chief R&D Officer Monika Tornsen - COO & Presiden...